Key Highlights

  • Net loss per share was USD 0.26, against an estimate of a USD 0.27 loss.
  • Net loss narrowed to USD 16.15 million from USD 17.20 million.
  • License and collaboration revenues were USD 736 thousand, against USD 16 thousand.
  • Cash and cash equivalents were USD 16.50 million at September 30, 2026.

Connect Biopharma (NASDAQ:CNTB) recorded license and collaboration revenues of USD 736 thousand in the third quarter of 2026, up from USD 16 thousand a year earlier. The net loss narrowed to USD 16.15 million from USD 17.20 million, and basic and diluted net loss per ordinary share was USD 0.26, compared with USD 0.31, against an estimate of a USD 0.27 loss.

Based in San Diego, California, the company presents itself as a clinical-stage drug developer whose mission is to change how asthma and chronic obstructive pulmonary disease are treated.

Spending in the Quarter

Research and development expense rose to USD 12.79 million from USD 11.11 million, while general and administrative expense fell to USD 4.26 million from USD 6.58 million. Total operating expenses were USD 17.05 million, compared with USD 17.69 million, and the loss from operations was USD 16.31 million, compared with USD 17.68 million.

Interest income was USD 185 thousand, compared with USD 545 thousand, and total other income, net, was USD 182 thousand, compared with USD 538 thousand. Income tax expense was USD 20 thousand. Weighted average ordinary shares outstanding were 62,974 thousand, compared with 55,716 thousand.

Nine Months to September 30

Over the nine months ended September 30, 2026, license and collaboration revenues reached USD 3.67 million, compared with USD 64 thousand. Research and Development expense was USD 44.09 million, compared with USD 26.52 million, and general and administrative expense was USD 13.10 million, compared with USD 16.10 million.

The loss from operations was USD 53.52 million, compared with USD 42.55 million, and the net loss was USD 52.83 million, compared with USD 40.37 million. Basic and diluted net loss per ordinary share was USD 0.87, compared with USD 0.73, and the comprehensive loss was USD 52.52 million, compared with USD 39.98 million.

Cash, Funding and Going Concern Doubt

Cash and cash equivalents were USD 16.50 million at September 30, 2026, compared with USD 38.35 million at December 31, 2025, and short-term investments were USD 2.99 million, compared with USD 6.00 million. Total Assets were USD 27.77 million, compared with USD 56.08 million, and total liabilities were USD 15.72 million, compared with USD 14.10 million. Total current liabilities were USD 15.50 million.

A private Placement during the nine months saw the company issue 6,130 thousand ordinary shares for net proceeds of USD 18.58 million once issuance costs were deducted. The filing says its liquid resources will not cover expected cash requirements for a minimum of one year from the filing date, and it discloses substantial doubt about going concern status.